TP53 and acute myeloid leukemia: According to the ICC criteria, AML-TP53 showed the shortest OS, followed by AML-MR (M or C) and AML-NOS (3.0 months [95% CI: 2.0–6.0] vs. 13.0 months [95% CI: 10.0–17.0] vs. 21.0 months [95% CI: 15.0–31.0], p < 0.0001) (Fig. 2I).